SeaStar Medical Holding Corp
No SEC Form 4 filings for $ICU in the last 30 days.
See all $ICU insider activity →SeaStar Medical (ICU) reported that its QUELIMMUNE (SCD-PED) treatment showed a 65.1% 90-day survival rate in pediatric sepsis patients, compared to 47.4% in a historical cohort. The data, presented at ASN Kidney Week 2026, also showed no device-related adverse events. The company's stock is traded on Nasdaq.
SeaStar Medical (ICU) received FDA Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients. This designation accelerates development and review. Sepsis affects 1.7M U.S. adults annually, with high mortality rates. The company plans to submit data to the FDA soon. This is the seventh such designation for the SCD therapy across various indications.
SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds DENVER, CO., October 5, 2026 – SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatmen
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ICU (SeaStar Medical Holding Corp). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ICU coverage spans regulation, corporate actions and financial news.
Positive trial data likely lifts ICU shares as market prices in the survival benefit.
Positive regulatory news likely lifts SeaStar Medical's valuation.
The warrant exercise provides cash but adds dilution, likely causing modest downward pressure.
The cash raise adds modest liquidity but increases share count, likely weighing on the stock.
Regulatory coding approval could improve billing and adoption of the device.
AlphAI scores every news story that mentions ICU with an AI model for sentiment and relevance, and aggregates insider trades from SeaStar Medical Holding Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
SeaStar Medical (ICU) reported that its QUELIMMUNE (SCD-PED) treatment showed a 65.1% 90-day survival rate in pediatric sepsis patients, compared to 47.4% in a historical cohort. The data, presented at ASN Kidney Week 2026, also showed no device-related adverse events. The company's stock is traded on Nasdaq.
2 min readSeaStar Medical (ICU) received FDA Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients. This designation accelerates development and review. Sepsis affects 1.7M U.S. adults annually, with high mortality rates. The company plans to submit data to the FDA soon. This is the seventh such designation for the SCD therapy across various indications.
2 min readSeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds DENVER, CO., October 5, 2026 – SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatmen
1 min readSeaStar Medical (ICU) raised $3.3M from warrant exercises at $3.866/share, issuing new warrants with a $3.616 exercise price. Proceeds will fund corporate needs. ICU stock is down 23%, trading at $3.60.
2 min readNewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
2 min readSeaStar Medical (Nasdaq: ICU) announced a late-breaking presentation at ASN Kidney Week 2026, showcasing post-approval SAVE Registry data. The event is scheduled for October 22, 2026, in Denver. SeaStar's QUELIMMUNE, approved in 2024, treats life-threatening AKI in pediatric patients. The company is also running the NEUTRALIZE-AKI trial for adult AKI patients.
1 min readSeaStar Medical (ICU) announced new ICD-10-PCS codes for its SCD therapy in treating acute kidney injury (AKI). The codes streamline hospital billing and expand access to QUELIMMUNE therapy. The company expects this to support broader adoption and potential future indications. QUELIMMUNE showed a 77% survival rate in clinical trials, with no dialysis required for survivors.
2 min readMessinger Michael (Chief Financial Officer) purchased 750 shares of SeaStar Medical Holding Corp (ICU) at $3.27 on 2026-08-18.
1 min readSeaStar Medical Holding Corp (ICU) reported Q2 2026 net revenue of $615,000, up 82% year over year, and six-month net revenue of $1.1 million. Gross margin was 91%. Net loss was $3.7 million ($0.91/share). Cash was $7.0 million at June 30, 2026. QUELIMMUNE adoption reached 20 hospitals; NEUTRALIZE-AKI enrolled 223/339 patients.
12 min readSeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates Added 3 top-rated children ’ s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enro
7 min read
